(Hum Exp Toxicol[TA])
4,307 results
  • Stevioside inhibits colorectal cancer progression by regulating macrophage polarization. [Journal Article]
    Hum Exp Toxicol. 2026; 45:9603271251365660.Bai Y, Wang Y, … Wang KHE
  • ObjectiveThe study aimed to explore the inhibitory effect of stevioside on colorectal cancer and its molecular mechanism.MethodsColorectal cancer cells were selected for functional testing, including the following groups: 0 μM stevioside, 1 μM stevioside, 2.5 μM stevioside and 5 μM stevioside. CCK-8 kit and EdU staining were employed to assess the cell viability. Cell apoptosis was deterred by fl…
  • Predictive factors of severe outcome in glufosinate ammonium poisoning: A retrospective study in Vietnam. [Journal Article]
    Hum Exp Toxicol. 2025; 44:9603271251412632.Nguyen DD, Anh Lam NH, Nguyen DBHE
  • BackgroundGlufosinate ammonium (GLA) is a widely used herbicide in rural Vietnam, often associated with severe toxicity. Given the limited diagnostic resources at primary care levels, identifying simple and effective predictors of severity is critical for early triage and intervention.ObjectiveTo identify clinical and biochemical predictors of severe outcomes in patients with glufosinate ammonium…
  • Nickel; a metal with threats to human health, focusing on its intoxication mechanisms. [Review]
    Hum Exp Toxicol. 2025 Jan-Dec; 44:9603271251361197.Rafati Rahimzadeh M, Rafati Rahimzadeh M, … Moghadamnia AAHE
  • Background and ObjectiveNi is an important metal found in the human environment, including air, water, soil, food, kitchenware, and jewelry. It is widely used in electrical engineering, medicine, and industry. Ni compounds, whether insoluble (such as oxides and sulfides) or soluble (such as sulfates, chlorides, and acetates), pose serious risks to the environment, ecosystems, and human health. Su…
  • Bardoxolone methyl triggers Ferroptosis in cardiomyocytes. [Journal Article]
    Hum Exp Toxicol. 2025; 44:9603271251394706.Li H, Hong M, … Zheng FHE
  • IntroductionBardoxolone methyl (Bardo), a Kelch-like ECH-associated protein 1 (Keap1)-Nrf2 pathway activator, has demonstrated efficacy in slowing eGFR decline in diabetic kidney disease (DKD). However, its Phase 3 trial in stage 4 DKD was terminated owing to unexpected cardiovascular complications.MethodsTo explore the underlying mechanisms, the human cardiomyocyte cell line AC16 was subjected t…